LED Dental Says VELscope Vantage Exceeding Expectations

LED Dental Says VELscope Vantage Exceeding Expectations
2nd Generation Technology Receiving Warm Reception from Dental Marketplace

WHITE ROCK, British Columbia—September 29, 2008—LED Dental announced today that sales of its recently introduced VELscope Vantage Oral Cancer are exceeding expectations and helped drive company revenues well above prior year levels for the May-September period. The VELscope Vantage system offers the following special features not offered in the original VELscope device: more powerful lamp technology providing improved fluorescence and camera imaging; a two-year comprehensive warranty; enough disposable products to cover 200 screenings; a camera adapter kit for digital photography; and access to several continuing education courses related to use of the VELscope system.

“Despite its higher price tag, the VELscope Vantage is clearly being appreciated by customers for the truly outstanding value it represents,” said David Cox, president and chief operating officer of LED Dental. “If practices charge only a nominal fee of around $35 for a VELscope screening, the system will be fully paid for by the time the practice consumes the disposables that come with it. And for most practices, that could take only two or three months.” The VELscope Vantage has also picked up some industry accolades during its first several months in the market, including being named one of the 2008 “Top 100 Products” by Dentistry Today magazine.

According to David Taylor, LED Dental’s senior vice president for sales and marketing, “As the only device on the market cleared by the FDA to help discover precancer and early stage cancer that may not be apparent to the naked eye, the VELscope Vantage is clearly establishing itself as the dental practice’s best opportunity to help reduce the incidence of oral cancer and other oral mucosal diseases.”

About LED Dental

LED Dental Inc. is a wholly-owned subsidiary of LED Medical Diagnostics Inc., which was founded in 2003 and is headquartered in White Rock, British Columbia, Canada. For more information, call 1-888-541-4614, or visit www.VELscope.com.

LED Medical Diagnostics Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward- looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by the company) contains statements that are forward-looking, such as statements relating to anticipated future revenues of the company and success of current product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of the company. For a description of additional risks and uncertainties, please refer to the company’s filings with the Securities and Exchange Commission.

<< Back